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Background Highly sensitive, commercial nucleic acid
ampliﬁcation tests (NAAT) for Trichomonas vaginalis have
only recently been recommended for use in the UK. While
testing for T. vaginalis is routine in symptomatic women
attending genitourinary medicine (GUM) clinics, it is rare in
asymptomatic women or those attending primary care. The
aim of this study was to evaluate the positivity of T.
vaginalis using a commercial NAAT, in symptomatic and
asymptomatic women undergoing testing for chlamydia and
gonorrhoea in GUM and primary care settings.
Methods Samples from 9186 women undergoing
chlamydia and gonorrhoea testing in South West England
between May 2013 and Jan 2015 were also tested for T.
vaginalis by NAAT alongside existing tests.
Results T. vaginalis positivity using NAAT was as follows:
in GUM 4.5% (24/530, symptomatic) and 1.7% (27/1584,
asymptomatic); in primary care 2.7% (94/3499,
symptomatic) and 1.2% (41/3573, asymptomatic).
Multivariable regression found that in GUM older age, black
ethnicity and deprivation were independent risk factors for
T. vaginalis infection. Older age and deprivation were also
risk factors in primary care. Testing women presenting with
symptoms in GUM and primary care using TV NAATs is
estimated to cost £260 per positive case diagnosed
compared with £716 using current microbiological tests.
Conclusions Aptima TV outperforms existing testing
methods used to identify T. vaginalis infection in this
population. An NAAT should be used when testing for
T. vaginalis in women who present for testing with
symptoms in primary care and GUM, based on test
performance and cost.
BACKGROUND
Trichomonas vaginalis is the most common non-
viral STI worldwide with an estimated 276 million
new cases annually.1 In the USA, 3.15% of women
of reproductive age are estimated to be infected,
corresponding to 2.31 million prevalent infec-
tions.2–4 T. vaginalis infection is associated with
female gender, non-Hispanic black race/ethnicity,
older age, a greater number of lifetime sex part-
ners, lower educational level and poverty.2–4
T. vaginalis infection is associated with adverse
pregnancy outcomes including premature rupture of
membranes, preterm labour and low birth weight.2 5
There is increasing recognition that T. vaginalis
increases the likelihood of HIV acquisition, HIV
shedding and onward transmission.2 6–9 This inter-
action with HIV could increase the cost-
effectiveness of T. vaginalis testing in areas or popu-
lations with moderate to high HIV incidence.2 10 11
Highly sensitive nucleic acid ampliﬁcation tests
(NAATs) for T. vaginalis, approved by the FDA, are
available in Europe and the USA.2 12 13
Data from Public Health England in 2015
showed 6396 new diagnoses of T. vaginalis com-
pared with >200 000 chlamydia diagnoses.14 The
Natsal-3 study estimated the British general popula-
tion T. vaginalis positivity as 0.3%.15
At the start of this study, routine clinical practice
in the UK was to test symptomatic women attend-
ing genitourinary medicine (GUM) clinics for
T. vaginalis infection, using culture and wet mount
microscopy. In 2014, updated BASHH guidelines
recommended T. vaginalis NAAT testing in GUM
for symptomatic women, where resources allow;16
however, availability remains limited.
One such NAAT, the Aptima T. vaginalis transcrip-
tion-mediated ampliﬁcation test (Aptima TV; Hologic,
San Diego, USA), has shown acceptable performance
characteristics in the UK and USA.12 17 18 It is not
known which other patient groups could beneﬁt
from T. vaginalis testing using NAAT or whether
testing would be considered good value for money.
In this study, we evaluate the positivity of
T. vaginalis in symptomatic and asymptomatic
women undergoing testing for Chlamydia trachoma-
tis and Neisseria gonorrhoeae in GUM and primary
care. We compare the new test with existing testing
practice and validate self-collected vaginal swabs.
Finally, we consider the economic implications in
each clinical setting of changing testing protocol, to




Bristol has a population of 442 500,19 20 with 16%
black minority ethnic. We recruited patients from
the Bristol GUM clinic (Bristol Sexual Health
Centre) and primary care practices in central and
South Bristol, Bath and Weston-Super-Mare.
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Study period
Data were collected from May 2013 to January 2015.
Eligibility
All females undergoing C. trachomatis and N. gonorrhoeae
NAAT testing were eligible. We excluded women who were
pregnant or under 18 years old.
Recruitment
GUM clinic
Women presenting for testing in GUM were asked about symp-
toms (vaginal discharge irritation, dysuria, pain).
Patients were managed according to routine clinical practice:
Group 1 (symptomatic) underwent speculum examination
and was asked to provide a self-collected vaginal swab. Genital
swabs were also collected by a health professional.
Group 2 (asymptomatic) provided a self-collected vaginal swab.
Primary care
Women were recruited from GP practices served by University
Hospitals Bristol, Weston General Hospital or Royal United
Hospital Bath laboratories.
Healthcare professionals submitting an electronic request for
chlamydia and gonorrhoea NAATwere offered Aptima TV auto-
matically. The test was offered consistently across all practices
served by the above laboratories for the duration of the study.
However, it was not possible to obtain information about
patients who opted out.
Women were asked about symptoms and assigned to group 3
(symptomatic) or group 4 (asymptomatic). Women from group
3 and 4 provided self-collected or clinician collected swabs
according to routine clinical practice in primary care.
Testing of samples
Aptima swab samples were tested for C. trachomatis and
N. gonorrhoeae using the Aptima Combo 2 C. trachomatis and
N. gonorrhoeae test (Hologic). The residual sample was tested
using Aptima TV. All test kits were provided free of charge by
Hologic.
Genital swabs in standard microbiological media were tested
for T. vaginalis using wet mount and culture according to exist-
ing testing protocols: All symptomatic patients with GUM had a
wet mount and culture for T. vaginalis. Samples from primary
care were tested using wet mount and culture, prepared from
charcoal transport swabs, dependent on the clinical details pro-
vided according to routine laboratory practice.
Consent
Written consent was obtained from patients in group 1, because
an additional sample was collected for validation of self-
collection swabs. Patients in groups 2–4 were notiﬁed of the
study using posters in the waiting rooms and clinical areas and
were included unless they opted out of the study.
Ethics
Ethical approval for this study was obtained from the NHS
Health Research Authority NRES Committee South West,
Cornwall and Plymouth (REC Reference: 12/SW/0181).
Data governance
All patient identiﬁable data were converted to suitable proxy
variables and then removed from the study database prior to
statistical analysis.
Analysis
Information on age, symptoms (present/absent) and the results
of all diagnostic tests performed for T. vaginalis, C. trachomatis
and N. gonorrhoeae was collected for all participants. In add-
ition, ethnicity and symptom details were collected for GUM
participants only (groups 1 and 2).
The index of multiple deprivation (IMD) is a composite score
indicating relative socioeconomic disadvantage, published by the
UK Ofﬁce for National Statistics (ONS),21 used under open
license (http://www.nationalarchives.gov.uk/doc/open-government-
licence/version/3/).
Deprivation scores were assigned to study individuals by
matching the LSOA codes to IMD scores from ONS data. For
GUM (groups 1 and 2) participants, the LSOA code was
derived from postcode of residence and for GP (groups 3 and
4) participants on their GP practice postcode.
All analyses were performed in STATAV.14 (Stata LP).
Sample size
We used group1 to examine the diagnostic accuracy of Aptima
TV compared with wet mount and culture. We estimated the
number of positive cases required (n=24) to show with 95%
power at an α of 0.05 that the diagnostic accuracy of Aptima
TV was the same as that of wet mount and culture. We calcu-
lated the sample size (n=800 tests) based on the estimated
number positive and the positivity of T. vaginalis in this popula-
tion by existing tests prior to the study (3%). Since the interim
analysis in December 2014 indicated a higher observed positiv-
ity of T. vaginalis (4.6%), we revised our sample size calculation
(n=510 tests).
Collection of samples for groups 2–4 continued until we had
recruited the required number from group 1.
Statistical analysis
The following multivariable logistic regression analyses of
factors associated with T. vaginalis-positive test result were
performed:
1. All participants: independent variables: age, setting (GP or
GUM), symptoms (presence/absence), chlamydia diagnosis
(positive/negative), gonorrhoea diagnosis (positive/negative)
2. GUM only (groups 1 and 2) as above, IMD score (based on
postcode of residence), ethnic group)
3. Primary care only (groups 3 and 4) as above, IMD score
(based on practice postcode)
4. Performance of existing tests was compared with Aptima TV
using the χ2 test.
Economic evaluation
The costs of current and new testing methods were estimated.
These estimates took into account reagents and staff costs. Two
scenarios of costs for implementing T. vaginalis NAAT testing
were considered:
Scenario 1: using same NAAT platform,
additional test added to chlamydia and gonorrhoea NAAT,
where Aptima NAAT platform is in use (assumes Aptima TV
test cost £7.62).
Scenario 2: using different NAAT platform, stand-alone test
with a different sample from that used for chlamydia and gonor-
rhoea NAAT, where another NAAT platform is in use (assumes
Aptima TV cost £15.19).
The number of additional diagnoses, number of tests per-
formed, total cost of testing, cost per positive and cost per add-
itional positive in each group were calculated.
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RESULTS
A total of 9241 women were recruited to the study: 9220 were
eligible and 9186 had complete data on age and deﬁnitive test
results for T. vaginalis, C. trachomatis and N. gonorrhoeae sum-
marised in table 1. Study recruitment and exclusions are shown
in online supplementary appendix ﬁgure A1.
During the study period May 13 to January 15, there were a
total of 46 188 chlamydia/gonorrhoea NAATs performed on
female patients in the three laboratory areas. A total of 14 367
tests were performed in GUM of which 2114 (14.7%) were
included in the analysis and 31 821 were performed in primary
care of which 7072 (22.2%) were included in the analysis.
The positivity of T. vaginalis, C. trachomatis and N. gonor-
rhoeae is shown in ﬁgure 1 and online supplementary appendix
table A1.
Overall, the T. vaginalis positivity was 2.0% (95% CIs 1.75%
to 2.33%) compared with N. gonorrhoeae 0.4% (95% CIs
0.26% to 0.52%) and C. trachomatis 2.7% (95% CIs 2.4% to
3.08%).
The observed T. vaginalis positivity was highest in symptom-
atic patients with GUM 4.5% (24/530), followed by symptom-
atic women attending primary care (2.7%, 27/1584). In
symptomatic women attending primary care, the positivity of
T. vaginalis (2.7%) was higher than C. trachomatis (2.1%).
Risk factor analysis
In multivariable logistic regression of risk factors (n=9186), the
presence of symptoms, attendance at GUM, age over 35 and
chlamydia diagnosis were all signiﬁcantly associated with diag-
nosis of T. vaginalis at 5% signiﬁcance level (table 2).
In subgroup analysis in GUM, black ethnicity was associated
with increased odds of diagnosis with T. vaginalis (adjusted OR
5.28, CI 2.65 to 10.50, p<0.001) compared with white ethni-
city (see online supplementary appendix table A2).
In the primary care analysis, increasing risk with age remained
(see online supplementary appendix table A3). The effect of
deprivation was signiﬁcant in both settings (GUM and primary
care) with more deprived (higher) IMD scores associated with
higher risk of T. vaginalis.
Performance of new test compared with existing testing
practice
A total of 3424 (of the total 9186) patients were tested both by
Aptima TV and existing testing methods (either wet mount
microscopy, culture or both). The majority were symptomatic
(group 1: 485, group 2: 17, group 3: 2133, group 4: 789).
In the GUM clinic, where wet mount microscopy is under-
taken on site in addition to culture, existing testing methods were
56.5% (13/23) sensitive compared with the Aptima TV test.
In primary care, sensitivity was 25.7% (19/74), which may
reﬂect deterioration of samples in transit. There were no cases
identiﬁed by existing test methods which were not also identi-
ﬁed by Aptima TV, which signiﬁcantly outperformed existing
testing methods in GUM and primary care (p<0.001, χ2 test)
see online supplementary appendix table A4.
Clinician and self-collected swabs had equivalent performance
(details in online supplementary appendix table A5).
Economic evaluation
Table 3 shows the number of tests performed for T. vaginalis in
symptomatic and asymptomatic women in primary care and
GUM clinics (Row B), number of diagnoses (A) compared with
numbers tested under current testing policy (E) and diagnosed
by Aptima TV (C) or wet mount/culture (D). These results were
used to calculate the positivity and number of additional diagno-
ses and the cost implications of different testing strategies.
Compared with baseline estimates, for women currently
tested for T. vaginalis (3424) using Aptima TV would result in
an additional 45 diagnoses (97 compared with 32). If all
women who are currently tested for chlamydia/gonorrhoea
(9186) were also tested for T. vaginalis, this would result in 186
diagnoses (2.0% positivity).
Scenario 1 (using same testing platform) compared with
baseline
The total cost of universal testing for T. vaginalis in women cur-
rently receiving chlamydia/gonorrhoea testing assuming use of
existing NAAT platform is estimated at £69 997 over
21 months, equating to approximately £40 000 per year,
Table 1 Demographics of women in each study group
Group 1 Group 2 Group 3 Group 4 All groups
GUM, symptomatic GUM, asymptomatic Primary care, symptomatic Primary care, asymptomatic
Total (%) Total (%) Total (%) Total (%) Total (%)
n 530 1584 3499 3573 9186
Age <25 214 (40.4%) 654 (41.3%) 1113 (31.8%) 1545 (43.2%) 3526 (38.4%)
Age ≥25 316 (59.6%) 930 (58.7%) 2386 (68.2%) 2028 (56.8%) 5660 (61.6%)
Age range 18 to 66 18 to 72 18 to 72 18 to 80 18 to 80
Mean age 28.0 27.8 31.5 28.6 29.5
Median age 26 26 29 26 27
Ethnic group* N/A N/A N/A
White 434 (81.9%) 1352 (85.4%)
Black 46 (8.7%) 88 (5.6%)
Asian 12 (2.3%) 25 (1.6%)
Mixed 27 (5.1%) 68 (4.3%)
Other 9 (1.7%) 18 (1.1%)
Prefer not to say 0 (0.0%) 24 (1.5%)
Missing 2 (0.4%) 9 (0.6%)
Residence IMD mean score 24.5 23.0 – – –
Practice IMD mean score N/A N/A 28.5 25.5 26.9
*Ethnic categories following Office for National Statistics grouping, white (‘A’, ‘B’, ‘C’), black (‘M’, ‘N’), Asian (‘H’, ‘J’, ‘K’, ‘L’), mixed (‘D’, ‘E’, ‘F’, ‘G’), other (‘R’, ‘S’), prefer not to say (‘Z’).
GUM, genitourinary medicine; IMD, Index of Multiple Deprivation.
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depending on test volume. The overall cost per positive is £376,
compared with £849 per positive using current tests (table 3). If
only symptomatic women are tested (ie, combining group 1 and
3), the cost per positive would be £260=(530+3499)×£7.62/
(24+94) compared with £716=(485+2133)×£7.93/(12+17)
using current tests.
Scenario 2 (using a different testing platform) compared
with baseline
For clinics with different testing platforms, the total cost of uni-
versal testing for T. vaginalis is £139 535 (21 months study
period) or £79 700 per year. Correspondingly, the cost per posi-
tive is also nearly doubled.
This only includes the test cost and excludes equipment pur-
chase, lab overheads, training and other opportunity costs asso-
ciated with implementing a new laboratory test which should
also be considered.
DISCUSSION
Summary of main ﬁndings
In women attending primary care and at risk of STIs, positivity
of T. vaginalis infection was 2.7% (symptomatic) and 1.1%
(asymptomatic), using the Aptima TV test.
In women attending GUM, the positivity of T. vaginalis was
4.5% (symptomatic) and 1.7% (asymptomatic) which is consist-
ent with comparable UK NAATestimates.22
Aptima TV outperformed existing testing methods, identify-
ing additional cases of T. vaginalis in GUM and primary care
settings.
T. vaginalis positivity was 11.9% (16/134) in patients of black
ethnicity in GUM and 1.6% (29/1789) in those who self-
identiﬁed as white. However, as the absolute number of cases
was higher in women of white ethnicity, 69% (35/51) of T. vagi-
nalis NAAT-positive cases in GUM would not have been identi-
ﬁed had testing been targeted based on black ethnicity alone.
Figure 1 Positivity of Trichomonas
vaginalis, Chlamydia trachomatis,
Neisseria gonorrhoeae or any STI in
different patient groups. GUM,
genitourinary medicine.
Table 2 Logistic regression of risk factors for T. vaginalis diagnosis, with unadjusted and adjusted ORs (n=9186)
Variable Number (n=9186) TV positive (n=186) Positivity % (CI) Unadjusted OR (CI) p Value Adjusted OR p Value
Setting
Primary care 7072 135 1.91 (1.60 to 2.26) Ref
GUM 2114 51 2.41 (1.80 to 3.16) 1.27 (0.92 to 1.76) 0.150 1.73 (1.23 to 2.45) 0.002
Symptoms
Absent 5157 68 1.32 (1.03 to 1.67) Ref
Present 3911 118 2.93 (2.43 to 3.50) 2.26 (1.67 to 3.05) <0.001 2.28 (1.66 to 3.12) <0.001
Age group
18 to 24 3526 47 1.33 (0.98 to 1.76) Ref
25 to 34 3387 58 1.71 (1.30 to 2.21) 1.29 (0.88 to 1.90) 0.20 1.29 (0.87 to 1.90) 0.208
35 to 44 1359 39 2.87% (2.05 to 3.90) 2.19 (1.42 to 3.36) <0.001 2.26 (1.46 to 3.50) 0.001
45 and over 914 42 4.60 (0.33 to 6.16) 3.56 (2.34 to 5.44) <0.001 3.67 (2.38 to 5.67) <0.001
Chlamydia
Negative 8936 172 1.92 (1.65 to 2.23) Ref
Positive 250 14 5.60 (3.09 to 9.22) 3.02 (1.73 to 5.29) <0.001 3.64 (2.02 to 6.54) <0.001
Gonorrhoea
Negative 9152 32 2.01 (1.73 to 2.32) Ref
Positive 34 2 5.89 (0.72 to 19.68) 3.05 (0.72 to 12.81) 0.128 1.70 (0.37 to 7.75) 0.492
In the adjusted analysis, T. vaginalis positivity was the outcome adjusted for all variables (setting, symptoms, age group, chlamydia and gonorrhoea status).
GUM, genitourinary medicine.
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T. vaginalis infection was independently associated with
deprivation, and positivity was higher in older women in all
clinical settings.
The current cost of wet mount/culture is comparable to the
cost of an additional test in the existing testing platform in the
Bristol clinic, and the higher detection rate makes it relatively
more cost-effective as well as more accurate, especially for
patients in primary care.
Strengths and weaknesses
The study is a large, cross-sectional study of T. vaginalis infec-
tion diagnosed with NAATs in over 9000 women undergoing
STI testing and is the ﬁrst to report on T. vaginalis positivity in
primary care in the UK.
Study limitations
An important limitation of the study is that it does not include
any information about patient’s sexual behaviour, their partners
and their risks. It would have been useful to know partner’s eth-
nicity for those patients testing positive for T. vaginalis. In
primary care, ethnicity information is not consistently recorded
at patient or practice level.
Patients tested for STIs in primary care are likely at increased
risk compared with the general population and positivity would
be expected to be higher. In primary care, opportunistic chla-
mydia screening is recommended for sexually active women
under 25 years. Older women are not routinely screened and
might be more likely to present in the event of symptoms or
perceived risk. A limitation of this study is that it does not dis-
tinguish between patients in primary care who present in
response to symptoms or a perceived need to test and those
who are screened opportunistically. It was only possible to dis-
tinguish those who presented with and without symptoms.
We only included women over 18 so cannot comment on the
risk in younger women. We did not recruit patients from
community sexual health clinics, where positivity might be
lower than GUM but higher than primary care.
We do not have information on women who withheld
consent so cannot deﬁne the representativeness of the women in
each study group. We used opt-out consent method, other than
in symptomatic patients with GUM, which should reduce par-
ticipation bias.
The economic evaluation did not consider factors such as
indirect effects on population prevalence, such as reducing risk
of outcomes or the effect on HIV transmission. Local commis-
sioning decisions are likely to be based on pragmatic considera-
tions of cost and detection rate, which was the focus of this study.
Findings compared with other studies
In the USA in 2001–2004, the National Health and Nutrition
Examination Survey observed that 3.1% (n=3754) of women of
reproductive age were infected with T. vaginalis, with highest
rates in women of non-Hispanic black ethnicity (13.3%).3
Additional factors associated with infection were older age
(especially in black women), lower educational achievement and
poverty.3
In the Netherlands, a comparative cohort study observed
T. vaginalis infection in women in 1.6% of a general practice
cohort (n=554) and 0.8% of a nationally representative chla-
mydia screening study (n=566).23 In Australia, a retrospective
analysis of community samples tested with NAAT found 1.5%
(n=37 137) of women positive for T. vaginalis.24 Indigenous
referrals accounted for 48% of positive cases in this sample.24
The positivity in a general practice population is comparable
with the Netherlands and Australian ﬁndings23 24 and somewhat
lower than in USA, as expected. Findings from the GUM study
groups were also consistent with other comparable populations
in the UK.22
The positivity is much higher than that found in the recently
published Natsal-3 data15 which showed a 0.3% positivity in
Table 3 Economic implications for use of nucleic acid amplification test (NAAT) technology in different clinic settings (May 2013 to January
2015, 21 months)
Row
Genitourinary medicine Primary care Total
Symptomatic Asymptomatic Symptomatic Asymptomatic
Group 1 Group 2 Group 3 Group 4
All women in the study (tested for STI plus TV) Positive, TMA
(percentage)
A 24 (4.5%) 27 (1.7%) 94 (2.7%) 41 (1.1%) 186
(2.0%)
Total B 530 1584 3499 3573 9186
Women tested under current protocol Positive, TMA C 22 1 62 12 97
Positive, wet mount/
culture
D 12 1 17 2 32
Total tested E 485 17 2133 789 3424
Difference in diagnoses F=A–D 12 26 77 39 154
Positivity TMA test G=C/E 4.5% 5.9% 2.9% 1.5% 2.8%
Wet mount/culture H=D/E 2.5% 5.9% 0.8% 0.3% 0.9%
Baseline (current situation) Current cost I=E×£7.93 £3846 £135 £16 915 £6257 £27 152
Cost per positive (£7.93) J=I/D £321 £135 £995 £3128 £849
Scenario 1
TMA costs £7.62 using existing diagnostic
platform
Total cost (TMA test) K=B×£7.62 £4039 £12 070 £26 662 £27 226 £69 997
Difference in cost L=K–I £193 £11 935 £9748 £20 969 £42 845
Cost per additional
positive
M=L/F £16 £459 £127 £538 £278
Cost per positive N=K/A £168 £447 £284 £664 £376
Scenario 2
TMA costs £15.19, different test platform
Total cost (TMA test) O=B×£15.19 £8051 £24 061 £53 150 £54 274 £139 535
Difference in cost p=O–I £4205 £23 926 £36 235 £48 017 £112 383
Cost per additional
positive
Q=P/F £350 £920 £471 £1231 £730
Cost per positive R=O/A £335 £891 £565 £1324 £750
TMA, transcription-mediated amplification.
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4396 urine samples obtained from men and women aged
16–44 years. This suggests that the population who present for
testing in primary care is at higher risk than the general
population.
The Aptima TV test outperformed wet mount and culture in
the GUM clinic and particularly in primary care. Sensitivity of
wet mount and culture was 56.5% compared with NAATwhen
performed in the GUM clinic but was only 25.7% in primary
care. This could be due to deterioration of samples in transit,
calling into question the use of traditional microbiological
testing methods for T. vaginalis outside the GUM setting where
near patient wet mount microscopy is routinely available.
As has been shown previously for gonorrhoea and chlamydia,
self-collected swabs are as good as clinician-taken swabs for
T. vaginalis NAAT testing, and this is the preferred method for
sample collection.25
The association with black ethnicity has been documented
previously in the UK and USA3 22 26 The ﬁndings are consistent
with previous UK surveillance data which shows a higher pro-
portion of the absolute number of T. vaginalis diagnoses in
those of white ethnicity, but much higher rate of infection in
those of black ethnicity.
What this study means?
The positivity of T. vaginalis in women with symptoms in GUM
and in primary care was higher than anticipated using Aptima
TV. Opportunities for diagnosis of T. vaginalis may be being
missed in GUM and in primary care, and this could have impli-
cations for onward transmission and population positivity.
Use of sensitive NAATs such as Aptima TV will identify add-
itional cases, and is likely to be cost-effective for symptomatic
patients, especially when performed using the same sample and
diagnostic platform as that used for chlamydia and gonorrhoea
testing.
Use of NAATs in asymptomatic patients is more expensive.
Complex testing strategies based on a combination of risk
factors could help to optimise detection of T. vaginalis in the
community. These would need to be easy to implement in
practice.
Local epidemiology and locally relevant cost data will inﬂu-
ence commissioning decisions regarding T. vaginalis testing in
future in the UK.
Key messages
▸ Positivity of Trichomonas vaginalis determined by nucleic
acid ampliﬁcation tests (NAATs) is high in women with
symptoms presenting for STI testing in genitourinary
medicine (GUM) (4.5%) and in primary care (2.7%).
▸ In this UK population, deprivation increases the risk of
T. vaginalis independent of ethnicity.
▸ Based on cost, NAATs for T. vaginalis are recommended for
symptomatic women presenting for STI testing both in GUM
and primary care.
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